Development of Combination Vaccine Conferring Optimal Protection against Six Pore-Forming Toxins of Staphylococcus aureus

In the Gram-positive pathogen Staphylococcus aureus, pore-forming toxins (PFTs), such as leukocidins and hemolysins, play prominent roles in staphylococcal pathogenesis by killing host immune cells and red blood cells (RBCs). However, it remains unknown which combination of toxin antigens would induce the broadest protective immune response against those toxins. In this study, by targeting six major staphylococcal PFTs (i.e., gamma-hemolysin AB [HlgAB), gamma-hemolysin CB (HlgCB), leukocidin AB (LukAB], leukocidin ED (LukED], Panton-Valentine leukocidin [LukSF-PV], and alpha-hemolysin [Hla]), we generated 10 recombinant toxins or toxin subunits, 3 toxoids, and their rabbit antibodies. Using the cytolytic assay for RBCs and polymorphonuclear cells (PMNs), we determined the best combination of toxin antibodies conferring the broadest protection against those staphylococcal PFTs. Although anti-HlgA IgG (HlgA-IgG) showed low cross-reactivity to other toxin components, it was essential to protect rabbit and human RBCs and human PMNs. For the protection of rabbit RBCs, Hla(H35L) toxoid-IgG was also required, whereas for human PMNs, LukS-IgG and LukA(E323A)B-IgG were essential too. When the toxin/toxoid antigens HIgA, LukS-PV, Hla(H35L) and LukA(E323A)B were used to immunize rabbits, they increased rabbit survival; however, they did not block staphylococcal abscess formation in kidneys. Based on these results, we proposed that the combination of HIgA, LukS, Hla(H35L), and LukA(E323A)B is the optimal vaccine component to protect human RBCs and PMNs from staphylococcal PFTs. We also concluded that a successful S. aureus vaccine requires not only those toxin antigens but also other antigens that can induce immune responses blocking staphylococcal colonization.

Automated summary

The study investigated which combination of toxin antigens would induce the broadest protective immune response against Staphylococcus aureus PFTs, identifying essential antibodies for protecting rabbit and human RBCs and PMNs. The researchers proposed a combination of HIgA, LukS, Hla(H35L), and LukA(E323A)B as the optimal vaccine component for protecting human RBCs and PMNs from staphylococcal PFTs, emphasizing the need for not only these toxin antigens but also other antigens to block staphylococcal colonization for a successful S. aureus vaccine.